文献速递心外重症与机械循环支持

右心室心肌做功评分用于晚期心衰右心功能评估

Advanced hemodynamics for right ventricular failure: Evaluating the use of the myocardial performance score.
PubMed 文献 · J Heart Lung Transplant · 2025-11-13

研究提出右心室心肌做功评分(RV-MPS),定义为(3×肺动脉搏动指数PAPI×右心室心脏做功输出RV-CPO)/2,并通过800例压力-容积环在体仿真及223例晚期心衰侵入性血流动力学检查患者进行验证。结果显示RV-MPS是1年死亡或需心脏替代治疗的独立预测因子,且在左心室辅助装置植入前RV-MPS<0.5者术后右心衰发生率更高(66.7% vs 16.7%,p=0.003)。

要点

  • RV-MPS由PAPI与RV-CPO组合计算,仿真中与右室功能相关。
  • RV-MPS是晚期心衰1年死亡或需心脏替代治疗的独立预测因子。
  • LVAD植入前RV-MPS<0.5者术后右心衰发生率显著升高。

核心结论

  • RV-MPS在仿真中是可靠的右室功能估计指标,并可独立预测晚期心衰患者死亡或需心脏替代治疗,或有助于预后评估。

主要发现

  • 仿真队列中RV-CPO中位数0.22瓦(IQR 0.08–0.33),RV耦合比中位数1.3(IQR 0.87–1.85),PAPI中位数2.2(IQR 1.2–3.5),RV-MPS中位数0.74(IQR 0.19–1.60)。
  • 仿真显示在各应激血容量与动脉阻力条件下,RV EES与RV机械效率升高均伴随RV-MPS升高。
  • 验证队列中RV-MPS(OR 0.64,95%CI 0.43–0.97,p=0.037)、基线肌酐(OR 0.71,95%CI 0.51–0.97,p=0.32)与PCWP(OR 1.05,95%CI 1.01–1.10,p=0.011)为1年复合终点(死亡及需心脏替代治疗)的独立预测因子。
  • 左心室辅助装置植入前(n=33),RV-MPS<0.5者右心衰发生率显著高于RV-MPS≥0.5者(66.7% vs 16.7%,p=0.003)。

关键数值与推荐

  • RV-MPS计算公式为(3×PAPI×RV-CPO)/2。
  • LVAD植入前RV-MPS<0.5提示术后右心衰风险升高(66.7% vs 16.7%,p=0.003)。

临床怎么用

  • 对晚期心衰患者可计算RV-MPS辅助评估右室功能与预后,LVAD植入前RV-MPS<0.5者需警惕术后右心衰。

局限性

  • 验证队列为单中心回顾性资料,LVAD亚组样本量仅33例,结论仍需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of the study is to assess a novel hemodynamic parameter, right ventricular myocardial performance score (RV-MPS), as a marker for right ventricular function and prognosis for advanced heart failure patients. METHODS: A total of 800 pressure-volume loop in silico simulations were performed at various hemodynamic conditions. RV-MPS was calculated as (3 × pulmonary artery pulsatility index [PAPI] × right ventricular cardiac power output [RV-CPO]) / 2. For the validation cohort, a total of 223 patients with advanced heart failure who underwent invasive hemodynamic testing from January 2013 to December 2019 were included. Advanced hemodynamic parameters, including RV-CPO, PAPI, and RV-MPS were calculated. RESULTS: In the simulation cohort, the median RV-CPO was (median 0.22, IQR: [0.08, 0.33] watts), RV coupling ratio was (median 1.3, IQR: [0.87, 1.85], and PAPI (median 2.2, IQR: [1.2, 3.5]), and the median RV-MPS was 0.74 (IQR: 0.19, 1.60). Simulations showed increases in RV EES and RV mechanical efficiency was associated with increase in RV-MPS for all conditions of stressed blood volume and arterial resistance. In the validation cohort, RV-MPS (OR: 0.64, 95% CI: [0.43, 0.97], p = 0.037), baseline creatinine (OR: 0.71, 95% CI: [0.51, 0.97], p = 0.32), and PCWP (OR: 1.05, 95% CI: [1.01, 1.10], p = 0.011) were independent predictors of composite outcome of death and need for heart replacement therapy at 1-year. Prior to left ventricular assist device implantation (n = 33), patients with RV-MPS <0.5 had significantly increased incidence of RV failure compared to patients with preserved RV-MPS ≥0.5 (66.7% vs. 16.7%, p = 0.003). CONCLUSIONS: RV-MPS is a reliable estimator of RV function on in silico simulations. RV-MPS was an independent predictor of death or need for heart replacement therapy and may have a role in prognostication of advanced heart failure patients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Han J, Siddiki M, Kalantari S, et al. Advanced hemodynamics for right ventricular failure: Evaluating the use of the myocardial performance score. J Heart Lung Transplant. 2025. PMID: 41241032. doi:10.1016/j.healun.2025.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。